表紙
市場調査レポート

EpiCast Report:ブドウ膜炎の疫学予測

EpiCast Report: Uveitis - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 284135
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
EpiCast Report:ブドウ膜炎の疫学予測 EpiCast Report: Uveitis - Epidemiology Forecast to 2022
出版日: 2013年09月25日 ページ情報: 英文 72 Pages
概要

世界の主要6ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国)におけるブドウ膜炎の発症件数は、2012年の223,559件から、2022年には245,353件まで増加する(年間平均増加率0.97%)と予測されています。

当レポートでは、世界の主要6ヶ国におけるブドウ膜炎について取り上げ、危険因子の概要と世界の動向、疫学予測、疫学レポート、疾患動向の分析を提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
    • 喫煙は、ブドウ膜炎のリスクを高め、合併症のリスクも上昇させる
    • 若年性突発性関節炎(JIA)患者は、定期的な眼科検診が必須
    • HLA陽性抗原は、特定の種類のブドウ膜炎に関係
    • ブドウ膜炎は、様々な自己免疫性・神経系・伝染性の疾患に関連
  • 世界の動向
    • 米国
    • EU5ヶ国
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法:発症件数
    • 予測の前提条件と手法:有病件数
    • 予測の前提条件と手法:病因・解剖学的分布
    • 予測の前提条件と手法:疾患の経過
    • 予測の前提条件と手法:疾患の重症度
  • ブドウ膜炎の疫学予測
    • 発症件数
    • 年齢階級別発症件数
    • 性別発症件数
    • 年齢調整発症率
    • 発症件数:解剖学的部位別
    • 発症件数:病因別
    • 発症件数:疾患の経過別
    • 発症件数:重症度別
    • 有病件数
    • 年齢階級別有病件数
    • 性別有病件数
    • 有病件数:解剖学的部位別
    • 有病件数:病因別
  • 議論
    • 疫学予測の考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER038

Summary

Uveitis is a serious eye condition that often results in permanent vision damage due to frequent recurrence even after treatment. It consists of a group of diseases that present with inflammation of the uvea, can occur in one or both eyes, and may also affect the adjacent tissues such as the retina, optic nerve, and vitreous humor. Symptoms may include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. Uveitis has a wide variety of causes such as autoimmune disorders, infectious agents, or toxins; however, the cause is often unknown for a significant proportion of the cases.

In 2012, GlobalData epidemiologists forecast the 6MM had 223,559 incident cases of uveitis, 75% of which (168,264 cases) occurred in the US. Incident cases in the 6MM are expected to increase slightly to 245,353 cases by 2022, at the rate of 0.97% per year. In 2012, the 6MM had 665,778 prevalent cases of uveitis, which will increase to 730,913 cases in 2022 at the rate of 0.98% per year. The US also had the largest proportion of prevalent cases in 2012 (53.69%, 357,483 cases) out of all markets covered in this analysis. The forecast further shows anterior uveitis is the most common form of uveitis and non-infectious uveitis is the most common etiology among the 6MM.

This forecast provides detailed, granular, and clinically relevant segmentations of uveitis cases. The segmentations will allow for improved understanding of the disease and the ability to focus on specific subgroups within the disease. The analysis is further strengthened by the adherence to the standard clinical reporting guidelines from the International Uveitis Study Group (IUSG) and Standardization of Uveitis Nomenclature (SUN) Working Group. Using standard guidelines across the 6MM allows for meaningful comparisons across the markets and ensures these results will be relevant in reference to future studies, as the use of the guidelines are becoming more common in epidemiological research.

Scope

  • This report provides an overview of the risk factors, comorbidities and the global epidemiological trends for uveitis in the six major markets (6MM: US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year forecast of incident and prevalent cases of uveitis segmented by age, sex, primary anatomical location of inflammation (anterior, intermediate, posterior, panuveitis), and by etiology (infectious, non-infectious, idiopathic). Incident cases are further segmented by course of disease (acute, recurrent, chronic) and by severity (mild, moderate, severe).
  • The uveitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global uveitis market.
  • Quantify patient populations in the global uveitis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for uveitis therapeutics in each of the markets covered.
  • Identify the number of uveitis cases in each anatomical location category and in each etiology.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Smoking increases risk of uveitis and increases complications
    • 3.2.2. Juvenile idiopathic arthritis patients need regular ophthalmologic screenings
    • 3.2.3. HLA-positive antigens are linked to certain types of uveitis
    • 3.2.4. Uveitis is associated with various autoimmune, neurological, and infectious diseases
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, Incident Cases
    • 3.4.4. Forecast Assumptions and Methods, Prevalent Cases
    • 3.4.5. Forecast Assumptions and Methods, Etiological and Anatomical Distribution
    • 3.4.6. Forecast Assumptions and Methods, Course of Disease
    • 3.4.7. Forecast Assumptions and Methods, Disease Severity
  • 3.5. Epidemiological Forecast of Uveitis (2012-2022)
    • 3.5.1. Incident Cases of Uveitis
    • 3.5.2. Age-Specific Incident Cases of Uveitis
    • 3.5.3. Sex-Specific Incident Cases
    • 3.5.4. Age-Standardized Incidence Rates
    • 3.5.5. Incident Cases by Anatomical Location
    • 3.5.6. Incident Cases Segmented by Etiology
    • 3.5.7. Course of Disease of Incident Uveitis Cases
    • 3.5.8. Severity of Incident Uveitis Cases
    • 3.5.9. Prevalent Cases of Uveitis
    • 3.5.10. Age-Specific Prevalent Cases of Uveitis
    • 3.5.11. Sex-Specific Prevalent Cases of Uveitis
    • 3.5.12. Prevalent Cases by Anatomical Location
    • 3.5.13. Prevalent Cases by Etiology
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Diseases Most Frequently Associated with Uveitis
  • Table 2: Distribution of Uveitis by Anatomical Location in Community and Referral Centers
  • Table 3: Distribution of Uveitis Cases by Anatomical Location of Inflammation, Europe
  • Table 4: IUSG/SUN Working Group Classification of Uveitis by Anatomical Location
  • Table 5: Clinical Classifications of Uveitis
  • Table 6: 6MM, Sources of Incidence and Prevalence of Uveitis in the 6MM
  • Table 7: Italy, Anatomy Classification Calculation
  • Table 8: US, Anatomical Locations of Uveitis for Incident and Prevalent Cases
  • Table 9: 6MM, Incident Cases of Uveitis, N (Column %), Select Years 2012-2022
  • Table 10: 6MM, Age-Specific Incident Cases of Uveitis, N (Row %), 2012
  • Table 11: 6MM, Sex-Specific Incident Cases of Uveitis, N (Row %), 2012
  • Table 12: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N (Row %), 2012
  • Table 13: 6MM, Incident Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012
  • Table 14: 6MM, Incident Cases of Uveitis Segmented by Etiology and Anatomical Location, N, 2012
  • Table 15: 6MM, Incident Cases of Uveitis by Course of Disease, N (Row %), 2012
  • Table 16: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012
  • Table 17: 6MM, Prevalent Cases of Uveitis, N (Column %), Select Years, 2012-2022
  • Table 18: 6MM, Age-Specific Prevalent Cases of Uveitis, N (Row %), 2012
  • Table 19: 6MM, Sex-Specific Prevalent Cases of Uveitis, N (Row %), 2012
  • Table 20: 6MM, Prevalent Cases of Uveitis by Anatomical Location of Inflammation, N (Row %), 2012
  • Table 21: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012
  • Table 22: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Anatomical Location, 2012

List of Figures

  • Figure 1: US, Age Distribution of Study Populations Compared with the US General Population
  • Figure 2: US, Sex-Ratio of Study Populations Compared with the US General Population
  • Figure 3: 6MM, Incident Cases of Uveitis, N, 2012-2022
  • Figure 4: 6MM, Age-Specific Incident Cases of Uveitis, N, 2012
  • Figure 5: 6MM, Sex-Specific Incident Cases of Uveitis, N, 2012
  • Figure 6: 6MM, Age-Standardized Uveitis Incidence, Cases per 100,000 Population, Men and Women, 2012
  • Figure 7: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N, 2012
  • Figure 8: 6MM, Incident Cases of Uveitis by Course of Disease, N, 2012
  • Figure 9: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012
  • Figure 10: 6MM, Prevalent Cases of Uveitis, N, 2012-2022
  • Figure 11: 6MM, Age-Specific Prevalent Cases of Uveitis, N, 2012
  • Figure 12: 6MM, Sex-Specific Prevalent Cases of Uveitis, N, 2012
Back to Top